Company:Exact Sciences

From HandWiki
Short description: American company in Madison, United States
Exact Sciences Corporation
IndustryMolecular diagnostics
Founded1995; 29 years ago (1995) in Marlborough, Massachusetts
  • Stanley Lapidus
  • Anthony P. Shuber
HeadquartersMadison, Wisconsin, U.S.
Key people
  • Kevin Conroy
  • (Chairman, President & CEO)
  • Jorge Garces
  • (Chief Science Officer)
ProductsCologuard, Oncotype DX, Oncotype MAP
RevenueIncrease US$2.08 billion (2022)
Increase US$−594 million (2022)
Decrease US$−624 million (2022)
Total assetsDecrease US$6.23 billion (2022)
Total equityDecrease US$3.04 billion (2022)
Number of employees
6,400 (Dec 2022)
Footnotes / references

Exact Sciences Corp. is a molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision oncological tests for other types of cancer.[3]


Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001. In the early years, there was much speculation that the company would be acquired by a competitor or exit the market; during this time the company's share price fell to less than one dollar.[4][5][6]

A significant turnaround in the company's fortunes began with the announcement of a mutual collaboration and licensing agreement between Exact Sciences and the Mayo Clinic in June 2009. In the same year, the company appointed Kevin Conroy as CEO & president and moved its head office to Madison, Wisconsin.[7][8][9][10]

In August 2014, Exact Sciences received premarket approval from the Food and Drug Administration for the use and marketing of its flagship product, Cologuard. This breakthrough heralded the beginning of a period of rapid growth for Exact Sciences and the start of its first foray into the acquisitions market.[11]

In August 2017, the company made its first major acquisition when it purchased Sampleminded, a healthcare information technology company based in Salt Lake City, Utah, for $3.2 million. This was followed by the January 2018 announcement that Exact Sciences had completed a $690 million convertible bond offering and the revelation that the company was to acquire Armune Bioscience, a cancer diagnostic developer based in Kalamazoo and Ann Arbor, Michigan (announced during that year's J.P Morgan Healthcare Conference).[12][13] Third-quarter financial reports revealed the price of the Armune Bioscience acquisition to be valued at $12 million, plus $17.5 million in incentives for certain milestones.[14] Later, in October 2018, Exact Sciences announced its purchase of Biomatrica, a developer of sample preservation technology based in San Diego, California.[15][16][17] Financial reports revealed the purchase price to be $20 million with an additional $20 million in incentives for certain milestones.[citation needed]

In summer 2019, Exact Sciences opened a new 169,000 square feet lab and warehouse facility to expand its testing capacity for Cologuard and, in its largest acquisition yet, announced its intention to buy Genomic Health, a genetic cancer detection company based in Redwood City, California, for $2.8 billion. The reason given for this latest acquisition was to both expand Exact Sciences' product portfolio through the addition of Genomic Health's OncotypeIQ suite of precision tests, and expand into other markets outside the US on the back of Genomic Health's existing network.[18][19][20][21] The deal with Genomic Health led to the opening of Exact Sciences offices in the United Kingdom , France , Germany , Italy and Japan , and the foundation of Exact Sciences International, with its headquarters initially in Geneva and later in Zug, Switzerland .[citation needed]

In March 2020, Exact Sciences purchased Paradigm Diagnostics and Viomics, two companies based in Phoenix, Arizona that would expand their lab testing and research and development capabilities.[22] Later, in October 2020, the company again announced a round of acquisitions - this time of Thrive Earlier Detection Corp. (based in Cambridge, Massachusetts) and Base Genomics (based in Oxford, England), two companies specializing in one of Exact Sciences' pipeline areas - blood-based cancer screening.[23]

Exact Sciences responded to the 2020 COVID-19 pandemic by temporarily refocusing a portion of its diagnostic capacity to testing for the disease. The company received FDA regulatory approval to provide home testing kits in April 2020, becoming one of the first companies in the U.S. to do so.[24]

In early 2021, Exact Sciences announced its acquisition of Ashion Analytics and plans to collaborate in research with TGen, the City Of Hope's Genomics Institute.[25] This news came shortly after the company's decision to purchase an exclusive-use license of TGen's proprietary liquid biopsy-based test technology, Tardis.[26]

Acquisition history

Exact Sciences' Cologuard screening laboratory and warehouse in Madison, Wisconsin.
A Cologuard test package, ready for return to the lab using the pre-paid UPS shipping label.

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Exact Sciences

Exact Sciences Corp.
(Founded 1995)

(Acq 2017)

Armune Bioscience
(Acq 2018)

(Acq 2018)

Genomic Health
(Acq 2019)

Paradigm Diagnostics
(Acq 2020)

(Acq 2020)

Thrive Earlier Detection Corp.
(Acq 2020)

Base Genomics
(Acq 2020)


Since 2009, Exact Sciences has maintained a collaboration with Mayo Clinic for its current and future products.[27] In 2009, Exact Sciences also completed a licensing agreement with Hologic for its molecular detection platform.[28] In April 2017, Exact Sciences and MDxHealth agreed to share technology on a variety of epigenetics and molecular diagnostics applications for five years.[29] In August 2018, Exact Sciences and Pfizer announced an agreement through 2021 to co-promote Cologuard.[30] In November 2018, Exact Sciences announced a partnership with Epic Systems for order entries.[31]

Exact Sciences has, since 2015, been sponsor of the Cologuard Classic, a professional golf tournament on the PGA Tour Champions tournament circuit held annually at the Catalina Course of the Omni Tucson National Resort, in Tucson, Arizona.[citation needed]


Product Cancer targeted Purpose Launch year Availability Additional information
Cologuard™ Colorectal Detection of colorectal neoplasia associated DNA markers and for the presence of occult haemoglobin in human stool 2014 United States only In August 2014, the U.S. Food and Drug Administration (FDA) approved the company's at-home multitarget stool DNA screening test called Cologuard, for the detection of colorectal cancers and pre-cancers.[32][33][34][35][36]
This test has a false positive rate of 13%.[37]
Oncotype DX® AR-V7 Nucleus Detect Prostate Detection of acquired resistance to AR-targeted therapy via liquid biopsy assay that analyzes circulating tumor cells in a patient's blood 2018 United States only Developed by Epic Sciences and commercialised through a partnership with Exact Sciences in the United States.
Oncotype DX® Breast DCIS Score Breast Genomic testing of a patient’s risk for a local recurrence of ductal carcinoma in situ or invasive carcinoma 2011 Over 90 countries
Oncotype DX® Breast Recurrence Score Breast Genome-based, comprehensive, individualized risk assessment for early-stage invasive breast cancer in adjuvant and neoadjuvant settings 2004 Over 90 countries Since 2015 access to Oncotype DX Breast Recurrence Score testing has been available to all eligible NHS patients in England [38]
Oncotype DX® Colon Recurrence Score Colorectal Genome-based test to quantify the risk of recurrence of patients with anatomic stage II, MMR-P and stage III A/B colon cancers 2010 Over 90 countries
Oncotype DX® Genomic Prostate Score Prostate Genomic assay testing for men with clinically low- or intermediate-risk cancer to help make treatment decisions at the time of diagnosis 2013 Over 90 countries
Oncotype MAP™ Pan Cancer Tissue Multiple Tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer 2020 United States only


Pipeline products include esophageal, breast, lung, liver, and pancreatic cancer testing. The company is also working with the Mayo Clinic to identify biomarkers associated with the 15 deadliest cancers.[39] Other initiatives focus on:[citation needed]

  • Using experience gained from the development of Cologuard to create a wider cancer detection platform
  • Expanding the range Oncotype IQ products to include liquid and tissue-based tests
  • Adapting biomarker-based technologies create a liquid biopsy capable of detecting cancers and precancers from a blood sample
  • Improving analytical sensitivity using the company's existing multi-marker approach to better identify cancerous samples


  1. "Exact Sciences Corporation 2022 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 21 February 2023. 
  2. Jeff Clemetson (22 March 2022). "Exact Sciences Expands San Diego Footprint". San Diego Business Journal. 
  3. Newman, Judy (31 Aug 2014). "Exact Sciences' Cologuard cancer test debuts" (in en). 
  4. "EXACT SCIENCES CORP (EXAS) IPO" (in en). 31 Jan 2001. 
  5. Hennessey, Raymond (1 Feb 2001). "Exact Sciences IPO Gains, Breaks Price-Cutting Trend" (in en). 
  6. Timmerman, Luke (18 Dec 2013). "Exact Sciences, Once Near Death, Bounces Back With Colon Cancer Test" (in en). 
  7. "Exact Sciences Corp". Bloomberg. 
  8. McBride, Ryan (18 Jun 2009). "Exact Sciences Moving to Wisconsin". Xconomy. 
  9. "EXACT Sciences Corporation Closes $8.2-Million Private Placement, Enters Into Licensing and Collaboration Agreement" (in en). 12 Jun 2009. 
  10. "Exact Sciences Licenses Mayo Clinic IP; Closes $8.2M Placement". GenomeWeb. 12 Jun 2009. 
  11. "Premarket Approval (PMA)" (in en). 13 Aug 2014. 
  12. "XMS Capital Partners Serves as Financial Advisor to Exact Sciences on $600 Million Convertible Notes Offering" (Press release). 24 Jan 2018.
  13. Sarah, Stevenson (26 Jan 2018). "Armune Bio's Cancer Detection Tech Finds New Home with Exact Sciences" (in en). 
  14. Newman, Judy (3 Nov 2018). "Exact Sciences signs deal with Epic Systems, hikes sales, widens losses" (in en). 
  15. Buchanan, Jeff (18 Oct 2018). "Exact Sciences Acquires San Diego Lab Equipment Supplier Biomatrica" (in en). 
  16. "Exact Sciences Acquires Sample Preservation Technology Provider Biomatrica" (in en). 18 Oct 2018. 
  17. House, Douglas (18 Oct 2018). "Exact Sciences acquires Biomatrica" (in en). 
  18. Williams, Nick (27 Jun 2019). "Exact Sciences opens new lab in Madison to process Cologuard test" (in en). 
  19. "Exact Sciences to buy Genomic Health for $2.8 billion" (in en). 29 Jul 2019. 
  20. Feroldi, Brian (29 Jul 2019). "Why Exact Sciences Is Sinking and Genomic Health Is Rising" (in en). 
  21. Flanagan, Cristin; Ahmed, Nabila (29 Jul 2019). "Exact Sciences to Buy Genomic Health for About $2.8 Billion" (in en). 
  22. "Phoenix Based Paradigm And Viomics Acquired by Exact Sciences". 6 March 2020. 
  23. "Exact Sciences stock soars with acquisitions of 2 blood-based cancer screening firms for $2.56B". 20 Oct 2020. 
  24. Boulton, Guy (31 Aug 2020). "Exact Sciences wins regulatory approval for home COVID-19 tests; home test must be ordered by clinician, then sent to lab for analysis" (in en). 
  25. Sciences, Exact (16 Feb 2021). "Exact Sciences to Acquire Ashion Analytics and Enter Research Collaboration with City of Hope's Genomics Institute, TGen" (in en). 
  26. Sciences, Exact (13 Jan 2021). "Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology" (in en). 
  27. "Exact Sciences Advances Pipeline Capabilities with Mayo Clinic" (in en). 20 May 2019. 
  28. "Exact Sciences licenses Hologic's Invader diagnostics line" (in en). 23 Oct 2009. 
  29. "MDxHealth, Exact Agree to Collaborate on Epigenetics and MDx" (in en). 17 Apr 2017. 
  30. "Xconomy: Exact Sciences Shares Rise After Company Unveils Pfizer Partnership" (in en). 22 Aug 2018. 
  31. Spitzer, Julie (12 Nov 2018). "Epic signs agreement with Exact Sciences: 4 things to know" (in en). 
  32. Philippidis, Alex (13 Aug 2014). "FDA Approves First Noninvasive Colorectal Cancer Test" (in en). 
  33. "FDA Approves First Non-invasive DNA Screening Test for Colorectal Cancer" (in en). 13 Aug 2014. 
  34. Warren, Rachel (13 Aug 2014). "FDA Approves DNA Screening Test for Colorectal Cancer" (in en). 
  35. Edney, Anna (12 Aug 2014). "Exact Sciences Wins U.S. Approval for Colon Cancer Test". Bloomberg. 
  36. Schattner, Elaine (6 Mar 2015). "For Colon Cancer Screening, Cologuard Test Offers A Solid New Option". Forbes. 
  37. Fisher, Deborah (31 Aug 2014). "Facts, Myths, and the Stool DNA Test" (in en). 
  38. Staff Reporter (5 Feb 2015). "UK's NHS Adopts NICE Advice to Provide Oncotype DX for Intermediate Risk Breast Cancer Patients" (in en). 
  39. "The Pipeline" (in en). 

External links